Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Sep;74(5):670–676. doi: 10.1038/bjc.1996.420

Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment.

A Håkansson 1, B Gustafsson 1, L Krysander 1, L Håkansson 1
PMCID: PMC2074699  PMID: 8845294

Abstract

Interferon alpha (IFN-alpha) has a documented activity against malignant melanoma with a response rate of only approximately 20%. It would therefore be of considerable importance if patients likely to respond could be identified. The degree of mononuclear cell infiltration in primary tumours has been reported to correlate with a favourable prognosis. This investigation used monoclonal antibodies, anti-CD4, -CD8 and -CD11c, to identify subsets of tumour-infiltrating mononuclear cells in fine needle aspirates to study whether the presence of such cells correlates with the therapeutic effect of IFN-alpha. Twenty-one patients with systemic and 20 with regional metastatic malignant melanoma were studied before initiation of IFN-alpha treatment. A statistically significant correlation (P < 0.001) was found between the occurrence of CD4+ lymphocytes in fine needle aspirates and the therapeutic benefit of IFN-alpha in patients with systemic disease. Ten out of 11 with moderate to high numbers of infiltrating CD4+ lymphocytes achieved tumour regression. In contrast, among patients with low numbers of these cells in metastatic lesions, nine out of ten had progressive disease. Similar results were found in patients with regional disease.

Full text

PDF
670

Images in this article

672Figure 1
on p.672
673Figure 2
on p.673
674Figure 3
on p.674

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aebersold P., Hyatt C., Johnson S., Hines K., Korcak L., Sanders M., Lotze M., Topalian S., Yang J., Rosenberg S. A. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. J Natl Cancer Inst. 1991 Jul 3;83(13):932–937. doi: 10.1093/jnci/83.13.932. [DOI] [PubMed] [Google Scholar]
  2. Balch C. M., Murad T. M., Soong S. J., Ingalls A. L., Halpern N. B., Maddox W. A. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg. 1978 Dec;188(6):732–742. doi: 10.1097/00000658-197812000-00004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Balkwill F. R. Interferons. Lancet. 1989 May 13;1(8646):1060–1063. doi: 10.1016/s0140-6736(89)92455-0. [DOI] [PubMed] [Google Scholar]
  4. Creagan E. T., Schaid D. J., Ahmann D. L., Frytak S. Recombinant interferons in the management of advanced malignant melanoma. Updated review of five prospective clinical trials and long-term responders. Am J Clin Oncol. 1988 Dec;11(6):652–659. doi: 10.1097/00000421-198812000-00013. [DOI] [PubMed] [Google Scholar]
  5. Gresser I. Biologic effects of interferons. J Invest Dermatol. 1990 Dec;95(6 Suppl):66S–71S. doi: 10.1111/1523-1747.ep12874776. [DOI] [PubMed] [Google Scholar]
  6. Hansen M. G., McCarten A. B. Tumor thickness and lymphocytic infiltration in malignant melanoma of the head and neck. Am J Surg. 1974 Oct;128(4):557–561. doi: 10.1016/0002-9610(74)90275-x. [DOI] [PubMed] [Google Scholar]
  7. Hurwitz P. J. Spontaneous regression of metastatic melanoma. Ann Plast Surg. 1991 Apr;26(4):403–406. doi: 10.1097/00000637-199104000-00016. [DOI] [PubMed] [Google Scholar]
  8. Hutchinson G. H., Heinemann D., Symes M. O., Williamson R. C. Differential immune reactivity of tumour-intrinsic and peripheral-blood lymphocytes against autoplastic colorectal carcinoma cells. Br J Cancer. 1981 Sep;44(3):396–402. doi: 10.1038/bjc.1981.197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jones P. C., Sze L. L., Liu P. Y., Morton D. L., Irie R. F. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst. 1981 Feb;66(2):249–254. [PubMed] [Google Scholar]
  10. Kang S., Barnhill R. L., Mihm M. C., Jr, Sober A. J. Histologic regression in malignant melanoma: an interobserver concordance study. J Cutan Pathol. 1993 Apr;20(2):126–129. doi: 10.1111/j.1600-0560.1993.tb00228.x. [DOI] [PubMed] [Google Scholar]
  11. Kirkwood J. M., Strawderman M. H., Ernstoff M. S., Smith T. J., Borden E. C., Blum R. H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996 Jan;14(1):7–17. doi: 10.1200/JCO.1996.14.1.7. [DOI] [PubMed] [Google Scholar]
  12. Knop J. Immunologic effects of interferon. J Invest Dermatol. 1990 Dec;95(6 Suppl):72S–74S. doi: 10.1111/1523-1747.ep12874780. [DOI] [PubMed] [Google Scholar]
  13. Kornstein M. J., Brooks J. S., Elder D. E. Immunoperoxidase localization of lymphocyte subsets in the host response to melanoma and nevi. Cancer Res. 1983 Jun;43(6):2749–2753. [PubMed] [Google Scholar]
  14. Larsen T. E., Grude T. H. A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I. 3. The relation between the tumour-associated lymphocyte infiltration and age and sex, tumour cell type, pigmentation, cellular atypia, mitotic count, depth of invasion, ulceration, tumour type and prognosis. Acta Pathol Microbiol Scand A. 1978 Nov;86A(6):523–530. [PubMed] [Google Scholar]
  15. Legha S. S. Current therapy for malignant melanoma. Semin Oncol. 1989 Feb;16(1 Suppl 1):34–44. [PubMed] [Google Scholar]
  16. McGovern V. J. Spontaneous regression of melanoma. Pathology. 1975 Apr;7(2):91–99. doi: 10.3109/00313027509092702. [DOI] [PubMed] [Google Scholar]
  17. Miescher S., Stoeck M., Qiao L., Barras C., Barrelet L., von Fliedner V. Preferential clonogenic deficit of CD8-positive T-lymphocytes infiltrating human solid tumors. Cancer Res. 1988 Dec 15;48(24 Pt 1):6992–6998. [PubMed] [Google Scholar]
  18. Miescher S., Whiteside T. L., Carrel S., von Fliedner V. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol. 1986 Mar 1;136(5):1899–1907. [PubMed] [Google Scholar]
  19. Poppema S., Bröcker E. B., de Leij L., Terbrack D., Visscher T., Ter Haar A., Macher E., Thé T. H., Sorg C. In situ analysis of the mononuclear cell infiltrate in primary malignant melanoma of the skin. Clin Exp Immunol. 1983 Jan;51(1):77–82. [PMC free article] [PubMed] [Google Scholar]
  20. Ronan S. G., Eng A. M., Briele H. A., Shioura N. N., Das Gupta T. K. Thin malignant melanomas with regression and metastases. Arch Dermatol. 1987 Oct;123(10):1326–1330. [PubMed] [Google Scholar]
  21. Rosenberg S. A., Packard B. S., Aebersold P. M., Solomon D., Topalian S. L., Toy S. T., Simon P., Lotze M. T., Yang J. C., Seipp C. A. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988 Dec 22;319(25):1676–1680. doi: 10.1056/NEJM198812223192527. [DOI] [PubMed] [Google Scholar]
  22. Rosenberg S. A., Spiess P., Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986 Sep 19;233(4770):1318–1321. doi: 10.1126/science.3489291. [DOI] [PubMed] [Google Scholar]
  23. Ruiter D. J., Bhan A. K., Harrist T. J., Sober A. J., Mihm M. C., Jr Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma. J Immunol. 1982 Dec;129(6):2808–2815. [PubMed] [Google Scholar]
  24. Søndergaard K., Hou-Jensen K. Partial regression in thin primary cutaneous malignant melanomas clinical stage I. A study of 486 cases. Virchows Arch A Pathol Anat Histopathol. 1985;408(2-3):241–247. doi: 10.1007/BF00707986. [DOI] [PubMed] [Google Scholar]
  25. Tefany F. J., Barnetson R. S., Halliday G. M., McCarthy S. W., McCarthy W. H. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol. 1991 Aug;97(2):197–202. doi: 10.1111/1523-1747.ep12479662. [DOI] [PubMed] [Google Scholar]
  26. Vose B. M., Moore M. Human tumor-infiltrating lymphocytes: a marker of host response. Semin Hematol. 1985 Jan;22(1):27–40. [PubMed] [Google Scholar]
  27. Whiteside T. L., Jost L. M., Herberman R. B. Tumor-infiltrating lymphocytes. Potential and limitations to their use for cancer therapy. Crit Rev Oncol Hematol. 1992 Jan;12(1):25–47. doi: 10.1016/1040-8428(92)90063-v. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES